Chinese Pharmacopoeia 2025 Edition: What It Means for PVC Packaging Materials

The Chinese Pharmacopoeia 2025 Edition (CP <2025>) represents the latest national standards for drug quality control in China, including comprehensive requirements for pharmaceutical packaging materials. For PVC sheet manufacturers serving the Chinese pharmaceutical market, CP <2025> establishes updated specifications for material composition, physical properties, and safety testing.

Key updates in CP <2025> relevant to PVC packaging materials include revised identification methods using infrared spectroscopy, updated limits for extractable substances, enhanced mechanical property requirements, and new guidelines for compatibility testing with specific drug formulations. These changes align China's pharmacopoeia standards more closely with international benchmarks set by USP and EP.

Green Medical Packing has proactively updated our quality control procedures and testing protocols to meet all CP <2025> requirements. Our medical-grade PVC sheets undergo comprehensive testing per CP <2025> specifications, including identification tests, transparency measurements, mechanical strength evaluation, and extractables assessment. Each production batch is accompanied by a Certificate of Analysis confirming compliance with CP <2025> standards.

Our commitment to multi-standard compliance — covering CP <2025>, USP <661>, EP 4.1.1, and ISO 15338 — ensures that pharmaceutical companies can rely on our materials for regulatory submissions across all major global markets, including China, the United States, and Europe.